本文選題：西那卡塞片 + 骨化三醇膠丸��； 參考：《中國臨床藥理學(xué)雜志》2017年23期

【摘要】：目的觀察西那卡塞片聯(lián)合骨化三醇膠丸治療血液透析伴高鈣血癥的臨床療效和安全性。方法將48例持續(xù)性血液透析伴高鈣血癥患者隨機(jī)分為對照組24例和試驗(yàn)組24例。對照組予以西那卡塞每次25 mg,qd,口服;試驗(yàn)組在對照組治療的基礎(chǔ)上,加用骨化三醇膠丸每次0.25μg,每周3次,口服。2組患者均治療3個月。比較2組患者的臨床療效、血清鈣和磷濃度、全段甲狀旁腺激素(I-PTH)水平,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對照組的總有效率分別為91.67%(22例/24例)和66.67%(16例/24例),差異有統(tǒng)計學(xué)意義(P0.05)。治療后,試驗(yàn)組和對照組的鈣濃度分別為(2.91±0.37)和(2.28±0.21)mmol·L~(-1),磷濃度分別為(1.35±0.17)和(1.55±0.21)mmol·L~(-1),I-PTH分別為(261.47±30.18)和(301.38±43.05)pg·m L~(-1),差異均有統(tǒng)計學(xué)意義(均P0.05)。試驗(yàn)組發(fā)生藥物不良反應(yīng)有肌肉疼痛、惡心嘔吐和高血壓,對照組發(fā)生藥物不良反應(yīng)有肌肉疼痛、惡心嘔吐和腹瀉。試驗(yàn)組和對照組的總藥物不良反應(yīng)發(fā)生率分別為12.50%和16.67%,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論西那卡塞片聯(lián)合骨化三醇膠丸治療血液透析伴高鈣血癥的臨床療效,可顯著地降低血清鈣和磷濃度、以及I-PTH水平,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Xenakaset tablets combined with ossification triol colloid pill in the treatment of hemodialysis with hypercalcemia. Methods 48 patients with continuous hemodialysis and hypercalcemia were randomly divided into control group (n = 24) and trial group (n = 24). The control group was given 25 mg / d of silacarabine, and the experimental group was treated with 0.25 渭 g of oscitic triol gel pill 3 times a week for 3 months on the basis of the treatment in the control group. The clinical efficacy, serum calcium and phosphorus concentrations, total parathyroid hormone (PTH) levels and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 91.67 and 22 / 24, respectively. The difference was statistically significant (P 0.05). After treatment, the calcium concentrations of the experimental group and the control group were 2.91 鹵0.37) and 2.28 鹵0.21)mmol / L ~ (-1), P = 1.35 鹵0.17) and 1.55 鹵0.21)mmol ~ (-1) ~ (-1) ~ (-1) PTH, respectively, and 301.38 鹵43.05)pg ~ (-1) 43.05)pg / L ~ (-1), respectively (P < 0.05). The adverse drug reactions in the trial group were muscle pain, nausea, vomiting and hypertension, while in the control group they were muscle pain, nausea and vomiting and diarrhea. The incidence of total adverse drug reactions in the test group and the control group were 12.50% and 16.67%, respectively, with no significant difference (P 0.05). Conclusion the clinical curative effect of Xinakaset tablet combined with ossifying triol colloidal pill on hemodialysis with hypercalcemia can significantly reduce serum calcium and phosphorus levels and I-PTH level and do not increase the incidence of adverse drug reactions.
【作者單位】： 唐山市工人醫(yī)院腎內(nèi)科;
【分類號】：R692.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 曹娟;;低鈣透析聯(lián)合碳酸鈣及骨化三醇膠丸治療繼發(fā)性甲狀旁腺功能亢進(jìn)的療效觀察[J];中國社區(qū)醫(yī)師;2014年23期

2 馮忖;;骨化三醇膠丸沖擊療法聯(lián)合高通量血液透析治療維持性血液透析患者繼發(fā)性甲狀旁腺功能亢進(jìn)療效觀察[J];河北中醫(yī);2012年11期

3 于建華,朱世銀;假高鈣血癥的實(shí)驗(yàn)室鑒別方法[J];臨床軍醫(yī)雜志;2002年02期

4 張惠莉;王友真;;高鈣血癥[J];青海醫(yī)藥雜志;1991年04期

5 董麗華;楊玲鳳;;1例惡性腫瘤致高鈣血癥患者的觀察與護(hù)理[J];現(xiàn)代護(hù)理;2006年25期

6 盛錦根;;脊髓損傷兒童的高鈣血癥[J];國外醫(yī)學(xué).神經(jīng)病學(xué)神經(jīng)外科學(xué)分冊;1979年06期

7 李紹強(qiáng);潘岐作;林云笑;蘇銘俊;張呈;陳昌南;朱家康;謝峰;;高鈣血癥并腎功能不全癌癥患者化療前透析治療的臨床研究[J];河北醫(yī)學(xué);2011年01期

8 錢宗薇;;高鈣血癥的實(shí)驗(yàn)室診斷[J];實(shí)用外科雜志;1988年08期

9 支小燕;;一例多發(fā)性骨髓瘤伴高鈣血癥的護(hù)理[J];藥物與人;2014年08期

10 茍靜鳳;;高鈣血癥致心電圖ST段縮短[J];中華保健醫(yī)學(xué)雜志;2013年03期

，

本文編號：1889076